FDA Approves Subcutaneous Vyvgart Hytrulo for Generalized Myasthenia Gravis
TUESDAY, June 27, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous injections for the treatment of generalized myasthenia gravis (gMG) in adult patients…
Learn More